Welcome to our dedicated page for Acurx Pharmaceuticals news (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals stock.
Acurx Pharmaceuticals, Inc. develops small-molecule antibiotics for difficult-to-treat bacterial infections through a Gram-positive selective spectrum approach targeting DNA polymerase IIIC. Its pipeline includes ibezapolstat for Clostridioides difficile infection and additional DNA pol IIIC inhibitor candidates directed at Gram-positive pathogens such as MRSA, VRE, drug-resistant Streptococcus pneumoniae and B. anthracis.
Recurring ACXP news covers antibiotic development updates, microbiome data, scientific conference presentations, intellectual property for DNA pol IIIC inhibitors, financial results, registered offerings, warrant activity and investor-presentation announcements.
Acurx Pharmaceuticals (NASDAQ: ACXP), a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult-to-treat bacterial infections, has announced a conference call to discuss its second quarter 2024 financial results. The call is scheduled for August 9, 2024, at 8:00 am ET, before the U.S. financial markets open.
The company's President and CEO, David P. Luci, along with CFO Robert G. Shawah, will host the call to present the financial results and provide a business update. Investors and interested parties can join the call using the provided toll-free number for U.S. participants or international access numbers.
Acurx Pharmaceuticals (NASDAQ: ACXP) presented results from the ibezapolstat Phase 2 clinical trial for C. difficile Infection (CDI) at the 17th Biennial Congress of the Anaerobe Society of the Americas. The study showed favorable gut microbiome changes, including increased Actinobacteria in treated patients. Results were consistent with earlier studies, demonstrating preservation of beneficial bacteria. Dr. Kevin Garey highlighted the robust microbiome development plan, predicting an anti-recurrence effect of ibezapolstat. The company is preparing for Phase 3 clinical trials following a successful FDA End-of-Phase 2 Meeting, with plans to expand internationally.
Acurx Pharmaceuticals (NASDAQ: ACXP) has announced the successful conclusion of an FDA End-of-Phase 2 meeting, allowing the advancement of ibezapolstat for the treatment of C. difficile Infection (CDI) to Phase 3 clinical trials. The FDA agreed on key trial elements including protocol design and patient population. The trials will involve 450 subjects using a Modified Intent-To-Treat (mITT) population. Ibezapolstat has received FDA's QIDP and Fast-Track Designation and recently obtained SME designation from the European Medicines Agency, enabling fee incentives for EU Marketing Authorization. Plans include initiating trials in the EU, UK, Japan, and Canada.
Acurx Pharmaceuticals (NASDAQ: ACXP) announced its Q1 2024 financial and operational results, highlighting significant progress in its clinical trials and business operations.
Key achievements include positive data from the Phase 2b trial of ibezapolstat, which showed superior results over vancomycin for treating CDI, with a 94% eradication rate of C. difficile by Day 3. The FDA has agreed on the Phase 3 program and NDA filing pathway. The European Medicines Agency designated Acurx as an SME, providing fee reductions and support.
Financially, Acurx ended Q1 2024 with $8.9 million in cash, up from $7.5 million at the end of 2023. The company reported a net loss of $4.4 million, driven by increased R&D and G&A expenses. 1,121,793 shares were sold under ATM financing, raising $4.4 million.
Further data and presentations are anticipated throughout 2024 at several scientific conferences.
Acurx Pharmaceuticals announced the presentation of the Phase 2 clinical trial results of ibezapolstat for C. difficile Infection at ESCMID Global 2024 Scientific Conference. The results showed ibezapolstat's effectiveness in treating CDI and its potential as a therapeutic option against antimicrobial-resistant strains.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.